Sign inJoin waitlistJoin the waitlist

Ronald Chen

Professor, Radiation Oncology · University of Kansas School of Medicine

Credentials: · · · · · · ·

History

University of Kansas School of Medicine
Present

Radiation Oncology
Mass General Brigham
2005–2009
Preliminary or Transitional Year
2004–2005
Harvard Medical School
2000–2004

Research

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options
The Journal of Urology · 2018 · 633 citations
Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer
JAMA · 2012 · Last of 11 authors · 347 citations
Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement
Journal of Clinical Oncology · 2016 · First of 12 authors · 300 citations

Andrew Wang
25 papers
PG
Paul Godley
24 papers
Matthew Nielsen
19 papers · 4 as a resident
Xinglei Shen
19 papers
Aaron Falchook
17 papers · 11 as a resident
Trevor Royce
17 papers · 11 as a resident
Karen Hoffman
12 papers · 1 as a resident
Jordan Holmes
11 papers · 8 as a resident
Paul Nguyen
11 papers · 2 as a resident
Angela Smith
10 papers
Daniel Spratt
10 papers
James Mohler
10 papers

Grants

University of Kansas Cancer Center Paul Calabresi K12 Career Development Award for Clinical Oncology
National Cancer Institute · K12
Contact PI · $1.7M · University of Kansas Medical Center
2023–2028
The University of Kansas Cancer Center
National Cancer Institute · P30
Project lead · $1.1M · University of Kansas Medical Center
2012–2027
Disseminating Decision Support to Men with Localized Prostate Cancer
National Institute of Nursing Research · R21
PI · $441.3K · University of Washington
2022–2024
Cancer Care Quality Training Program
National Cancer Institute · T32
PI · $880.6K · Univ of North Carolina Chapel Hill
2005–2023

Clinical trials

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
Principal investigator · Active not recruiting · Phase 3
NRG Oncology
2020–2031
Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy
Principal investigator · Completed
NRG Oncology
2019–2025
Using PROMIS as Part of Routine Clinical Care for Racially Diverse Prostate and Bladder Cancer Patients
Principal investigator · Completed
UNC Lineberger Comprehensive Cancer Center
2017–2018
Optimizing the Effectiveness of Routine Post-treatment Surveillance in Prostate Cancer Survivors
Principal investigator · Completed
Alliance Foundation Trials, LLC.
2016–2019